Hematology

Latest News

MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

July 31st 2025

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.

Gloved hands holding ALL blocks | Image credit: Sviatlana - stock.adobe.com
Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL

July 30th 2025

Previous research suggests patients exposed to polypharmacy have greater risks of mortality, adverse drug reactions, and longer hospitalizations. | Image Credit: fizkes - stock.adobe.com
Number of Medications a Strong Prognostic Indicator in Lymphoma, CLL, MM

July 29th 2025

The researchers emphasized the importance of preventing bleeding events through personalized use of antiplatelet or cytoreductive therapies and closer monitoring of high-risk patients. | Image credit: Matthieu - stock.adobe.com
Hemorrhagic Events After Essential Thrombocythemia Diagnosis Strongly Linked to Early Death

July 29th 2025

Black, Hispanic, and Pacific Islander patients generally experienced worse OS compared with White patients, while Asian patients had similar outcomes. | Image credit: Colored Lights - stock.adobe.com
Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities

July 28th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com
February 13th 2025

Rapid IV Isatuximab Could Shift Care Practices in MM

Kyle Munz
Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.
FDA approval | Image Credit: © wladimir1804 - stock.adobe.com
Published: February 12th 2025 | Updated: February 12th 2025

FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL

Maggie L. Shaw
Interim data from the ECHELON-3 trial previously showed that adding brentuximab vedotin to lenalidomide and rituximab improved overall survival among patients who have relapsed or refractory large B-cell lymphoma (R/R LBCL).
Patient talking to doctor in appointment. | Image credit: Chinnapong – stock.adobe.com
February 10th 2025

Academic Cancer Centers See Longer Survival in CLL, MCL Than Community Centers

Hayden E. Klein
Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, highlighting disparities in specialized cancer care.
Mikkael Sekeres, MD
February 7th 2025

Treosulfan Approval Offers Novel Option for Allo-HSCT Conditioning in AML/MDS

Rose McNulty Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly approved agent for allogeneic hematopoietic stem cell transplantation (allo-HSCT) conditioning in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Non-Hodgkin Lymphoma wordcloud | Image Credit: © kalpis-stock.adobe.com.jpeg
February 7th 2025

Refining Remission Assessment in Aggressive B-Cell Lymphomas

Maggie L. Shaw
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread implementation.
cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com
February 7th 2025

Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

Kyle Munz
The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.
Mikkael Sekeres, MD
February 6th 2025

Treosulfan Shown Effective, Safe as Conditioning for Allo-HSCT in AML/MDS

Mikkael A. Sekeres, MD Rose McNulty
Mikkael A. Sekeres, MD, of Sylvester Comprehensive Cancer Center, University of Miami, discussed data supporting the FDA approval of treosulfan as part of conditioning for allogeneic hematopoeitic stem cell transplantation (allo-HSCT).
Non-HodgkinLymphoma | Image Credit: © enterlinedesign-stock.adobe.com
January 30th 2025

SynKIR-310 Dosing for B-NHL Begins in CELESTIAL-301 Trial

Jordyn Sava
The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Extranodal NHL is not uncommon, comprising over 30% of NHL cases | image credit: Prostock Studio - stock.adobe.com
January 29th 2025

Study Expands Knowledge of Prognostic Markers in Extranodal NHL

Kyle Munz
Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper research considerations.
There remains a need for more diagnostic accuracy in cases of soft tissue NHL | image credit: phonlamaiphoto - stock.adobe.com
January 27th 2025

MRI, sIL-2R Combination Showcases Great Diagnostic Accuracy for Soft Tissue NHL

Kyle Munz
Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.
Kirollos Hanna, PharmD
January 25th 2025

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD
Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
FDA approved. | Image Credit: Pawel - stock.adobe.com
January 23rd 2025

Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS

Rose McNulty
The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com
January 21st 2025

High Infection Risk in MM: Insights From the Preimmunotherapy Era

Kyle Munz
Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.
First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com
January 18th 2025

Unmet Needs Remain in Secondary AML Following Treatment With HMAs

Rose McNulty
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Man donating blood | Image Credit: © New Africa - stock.adobe.com
January 17th 2025

5 Medications That Defer Blood Donation

Maggie L. Shaw
Experts stress that persons wanting to donate blood should not stop any medications they are on, with some deferrals being permanent and others temporary.
MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com
January 13th 2025

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

Kyle Munz
This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.
Donating blood can save more than 1 life | image credit: Creative Cat Studio - stock.adobe.com
January 10th 2025

5 Things to Know About Donating Blood

Kyle Munz
Here are 5 things individuals should know about the powerful impact of blood donation and the benefits becoming a donor can have for patients in need.
mRNA vaccines can boost T cell responses | image credit: myskin - stock.adobe.com
January 9th 2025

Study Advocates Immunological Value of COVID-19 Vaccination in MM

Kyle Munz
Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA vaccines could bolster immunity in this vulnerable population.
MRD ahead of allo-HSCT showed prognostic value in patients with AML and MDS. | Image credit: keetazalay - stock.adobe.com
January 6th 2025

MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS

Kimberly Rath, PharmD
A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.
Among 55 evaluable samples analyzed, QPOP achieved an 87.3% success rate in generating individualized drug sensitivity reports. | Image credit: Eleni - stock.adobe.com
January 6th 2025

Functional Precision Medicine Tool Predicts Treatment Response in AML

Kimberly Rath, PharmD
A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug combination sensitivities, paving the way for improved treatment strategies and outcomes in acute myeloid leukemia (AML).
Don M. Benson, MD, PhD, James Cancer Hospital
January 2nd 2025

Honoring Patient Wishes in Myeloma Treatment Journeys

Maggie L. Shaw
In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always striving to deliver personalized patient care.
ASH thumbnail
December 29th 2024

ICYMI: Highlights From ASH 2024

Maggie L. Shaw
The 66th American Society of Hematology (ASH) Annual Meeting & Exposition took place December 7-10, 2024, in San Diego, California; the 2025 meeting is currently scheduled to take place in Orlando, Florida, December 6-9.
MM Top 5 Thumbnail
December 24th 2024

Top 5 Multiple Myeloma Content of 2024

Maggie L. Shaw
Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.
A subpopulation of patients with CLL/SLL and secondary immunodeficiency disease carry increased infection risks | image credit: sdecoret - stock.adobe.com
December 19th 2024

Infection Rate More Than Doubles in CLL/SLL Accompanied by Secondary Immunodeficiency Disease

Karen Jacobson-Sive
Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Older patients with AML or MDS do not always receive the same care recommendations, a study found | image credit: Orawan - stock.adobe.com
December 19th 2024

Canadian Study Highlights Care Variability for Older Patients With MDS/AML

Kimberly Rath, PharmD
A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), emphasizing the need for evidence-based guidelines.
MDS graphic | Image Credit: © Sviatlana-stock.adobe.com
December 18th 2024

Luspatercept Promising Against Anemia in MDS

Kimberly Rath, PharmD
Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.
ICYMI: Highlights From IMS 2024
December 17th 2024

ICYMI: Highlights From IMS 2024

Maggie L. Shaw
The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.
MDS | Image Credit: © ibreakstock-stock.adobe.com
December 11th 2024

Molecular Lesions in Low-Risk Myelodysplastic Neoplasms Disrupt Prognostic Model for Leukemia

Karen Jacobson-Sive
Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially bone marrow blast percentage, drop their clinical significance once molecular lesions are included in prognostic scores.
CLL cells magnified/stained | image credit: jarun011 - stock.adobe.com
December 10th 2024

6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL

Jared Kaltwasser
Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.
Matias Sanchez, MD
December 2nd 2024

Balancing Cutting-Edge Therapies With Cost in Multiple Myeloma Treatment

Skylar Jeremias
Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of cell therapies and bispecific antibodies.
<12345678
...
28>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo